Kathryn Campbell FAIDH
Kathryn (Kathy) Campbell
BEc, FAICD, FCA, FCPA, FAIDH
Kathy has worked in healthcare across Australia and internationally for over twenty years. Her experience ranges across providers, clinical/research alliances , research institutes, and with consulting firms and vendors. She has been involved in a number of first in country initiatives.
Kathy is known for her ability to contextualise her experience to new settings and to both think strategically and ensure that change is embedded in a sustainable way. She is committed to improving the healthcare system to ensure that the benefits to consumers from new discoveries are enabled in an equitable, effective and efficient manner.
She has consulted to Melbourne Genomics, Queensland Genomics, developed a digital genomics roadmap for eHealth Qld and initiated, and Chaired a Precision Medicine Community of Practice.
Kathy has over ten years experience as a Non-Executive Director with complex not for profit and government organisations in the health, aged care and resources sectors.
Kathy joined InGeNA as the Independent Chair in early 2023 and has led the organisation through a strategic refresh and the incorporation process. Members recently voted for her to continue in this role as InGeNA becomes incorporated and moves to its next stage of maturity.
Independent Deputy Chair
Susan (Sue) McKean
MBL, MHsC (Risk Management), Grad. Dip Applied Corporate Governance. FGIA, FCIS, GAICD.
Sue McKean is an experienced Senior Executive and Company Secretary with extensive leadership experience in health and community services organisations.
Sue’s roles include Group Executive Governance for UnitingCare Queensland, one of Queensland’s largest private companies and prior to that was the Director of Risk and Quality for UnitingCare Health. Sue was the inaugural Company Secretary for Australian Regional and Remote Community Services and start-up Leap in! Australia.
Sue has a passion for navigating complex governance, risk and leadership requirements in different organisational and service settings and is an experienced leader in organisations undergoing transformation, and sectors responding to increasing transparency expectations and regulatory reform.
Sue has a track record of fostering positive relationships and stakeholder management to achieve strategic and operational outcomes and holds a Masters of Health Science (Risk Management), Masters of Business Law and Graduate Diploma of Applied Governance.
Member Elected Director
Mark is the co-founder and CEO of 23 Strands Pty Ltd (23Strands), and is utilising whole genome sequencing and Artificial Intelligence to unlock the power of patient’s genetic code to provide a more accurate pathway to better patient outcomes.
23Strands is currently commercialising genomics screening and diagnostics across Women’s and reproductive health and is a key industry partner in over $30 million of translational and AI based grants and initiatives.
Mark is an experienced Engineer and business manager with over 20 years’ experience in the health technology industry where he has worked at companies such as Cochlear, Micromedical, Ventracore and the Henry Schein Group. He has significant track record in the commercialization of health innovations across a range of diagnostic, pharmaceutical and device markets.
He also is a passionate advocate for early stage innovation in Australia and has been an active mentor and supporter to the start up ecosystems across health, biological sciences and financial innovation. He currently is a member of several successful businesses and not for profits and sits on an Early Stage Venture Capital Investment Committee.
Member Elected Chair
Robert (Rob) McBride
Dip Bus, Cert, Med Lab Science, Microbiology and Clinical Chemistry
Rob is the General Manager of Australia, New Zealand, Korea and Singapore for Illumina. Rob has worked in genomics for over 30 years and is passionate about improving human health by using genomic technologies. Prior to his appointment to General Manager, he led the sales and specialist teams in Asia Pacific and Japan.
Rob joined Illumina in 2013 as part of the Bluegnome acquisition, initially driving growth in the In-vitro fertilisation (IVF) and cytogenetic portfolios in Australia leading to 95% conversion to Illumina technology. He then moved into a specialist role driving Non-invasive prenatal testing (NIPT) adoption as it emerged as an important technology reducing invasive amniocentesis screening in Australia. This led to a global CEO circle award in 2015. He then led the first clinical sales team globally in Illumina growing clinical adoption not just in reproductive health but including oncology and genetic disease and took the Asia pacific and Japan territory to region of the year in 2020 and 2022.
Earlier in his career, he worked at the Women’s and Children’s hospital in the field of Cytogenetics and moved to the United Kingdom to work with the leading provider of Cytogenetic imaging systems, where he was responsible for the successful global commercialisation and launch of a cytogenetic imaging system for plants and animals. Rob returned to Australia in 2000 to regionally manage the Asia Pacific sales leadership. Later, Rob worked with a variety of companies in the medical field, specifically focused on Cardiology, radiology and laser dentistry.
Member Elected Director
Diana (Di) Nielson
BCom, Cert Nursing
Di is Head of Diagnostics at AstraZeneca ANZ and has over 35 years experience in healthcare and the pharmaceutical industry. For the last 8 years she has led the Diagnostics capability at AstraZeneca facilitating equitable and timely access to Genomics to support patient’s access to precision oncology. Di is passionate about the evolution and integration of genomics into routine healthcare.
She has strong relationships with an extensive network of National and International pathology and diagnostic providers regularly collaborating on key projects to enhance access to genomics for Australians.
Di has extensive commercial experience and currently sits on the Oncology Leadership Team at AstraZeneca. Prior to this she worked across the pharmaceutical industry in a variety of roles supporting the commercialisation of Precision Oncology medicines and identification of the associated biomarkers.
Member Elected Director
BAppS (Med Tech)
Carl is an experienced senior leader in the biotechnology and diagnostics industry with a focus on commercialisation, sales, marketing and business development.
He has considerable experience commercialising diagnostic products, both locally and globally. Based in the USA for 13 years, he served as Senior Vice President for Panbio USA Ltd and Vice-President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics (NASDAQ:DGX).
Since moving back to Australia Carl has held a number of executive roles including, Chief Business Officer at Benitec Biopharma Limited (ASX: BLT, NASDAQ: BNTC), CEO and Managing Director of Sienna Cancer Diagnostics Ltd (ASX: SDX), and Chief Operating Officer of BARD1(ASX:IIQ). More recently he was appointed Chief Commercial Officer of Genetic Technologies (ASX:GTG, NASDAQ :GENE). Carl has also assisted several Australian biotech companies with their commercialisation strategies, these companies include BCAL Diagnostics (ASX:BDX), Biotron (ASX: BIT) and Minomic International. He is also a Non-Executive Director of Sangui Bio, an unlisted private company.